Healthcare - Biotechnology - NASDAQ - US
$ 0.023
0 %
$ 532 K
Market Cap
-0.16
P/E
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.[ Read More ]
The intrinsic value of one PKBO stock under the base case scenario is HIDDEN Compared to the current market price of 0.023 USD, Peak Bio, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart PKBO
FINANCIALS
368 K
REVENUE
-1.36 K
OPERATING INCOME
-12.8 M
NET INCOME
-4.76 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
4.28 M
FINANCING CASH FLOW
0
REVENUE
0
OPERATING INCOME
3.97 M
NET INCOME
-2.37 M
OPERATING CASH FLOW
66.5 K
INVESTING CASH FLOW
2.95 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Peak Bio, Inc.
| Current Assets | 2.37 M |
| Cash & Short-Term Investments | 382 K |
| Receivables | 75.2 K |
| Other Current Assets | 1.92 M |
| Non-Current Assets | 222 K |
| Long-Term Investments | 16.5 |
| PP&E | 153 K |
| Other Non-Current Assets | 69.2 K |
| Current Liabilities | 20.5 M |
| Accounts Payable | 5.86 M |
| Short-Term Debt | 10.7 M |
| Other Current Liabilities | 3.94 M |
| Non-Current Liabilities | 231 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 231 K |
EFFICIENCY
Earnings Waterfall
Peak Bio, Inc.
| Revenue | 368 K |
| Cost Of Revenue | 107 |
| Gross Profit | 368 K |
| Operating Expenses | 1.25 K |
| Operating Income | -1.36 K |
| Other Expenses | 12.8 M |
| Net Income | -12.8 M |
RATIOS
99.97%
GROSS MARGIN
-0.37%
OPERATING MARGIN
-0.34%
NET MARGIN
0.01%
ROE
-0.05%
ROA
0.02%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Peak Bio, Inc.
| Net Income | -12.8 M |
| Depreciation & Amortization | 311 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 275 K |
| Change in Working Capital | 3.66 M |
| Others | 5.25 M |
| Free Cash Flow | -4.76 M |
Wall Street Analysts Price Targets
Peak Bio, Inc.
PKBO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Peak Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 27, 2023
|
Bought 338 USD
|
LaMond Stephen J
See Remarks |
+ 2600
|
0.13 USD |
|
1 year ago
Sep 26, 2023
|
Bought 390 USD
|
LaMond Stephen J
See Remarks |
+ 3000
|
0.13 USD |
|
1 year ago
Sep 18, 2023
|
Bought 575 USD
|
LaMond Stephen J
See Remarks |
+ 2500
|
0.23 USD |
|
1 year ago
Sep 15, 2023
|
Bought 3.17 K USD
|
LaMond Stephen J
See Remarks |
+ 11750
|
0.27 USD |
|
1 year ago
Sep 21, 2023
|
Bought 8.55 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 45000
|
0.19 USD |
|
1 year ago
Sep 20, 2023
|
Bought 5.7 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 30000
|
0.19 USD |
|
1 year ago
Sep 19, 2023
|
Bought 10.4 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 50000
|
0.207 USD |
|
1 year ago
Sep 18, 2023
|
Bought 575 USD
|
LaMond Stephen J
See Remarks |
+ 2500
|
0.23 USD |
|
1 year ago
Sep 15, 2023
|
Bought 7.15 K USD
|
LaMond Stephen J
See Remarks |
+ 26000
|
0.275 USD |
|
1 year ago
Sep 15, 2023
|
Bought 6.62 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 25000
|
0.265 USD |
|
1 year ago
Sep 14, 2023
|
Bought 5.2 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 20000
|
0.26 USD |
|
1 year ago
Sep 13, 2023
|
Bought 8.13 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 30000
|
0.271 USD |
|
1 year ago
Sep 12, 2023
|
Bought 4.68 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 17000
|
0.275 USD |
|
1 year ago
Sep 11, 2023
|
Bought 8.4 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 30000
|
0.28 USD |
|
1 year ago
Aug 31, 2023
|
Bought 0 USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 0
|
0 USD |
|
1 year ago
Aug 31, 2023
|
Bought 3.44 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 13000
|
0.265 USD |
|
1 year ago
Aug 30, 2023
|
Bought 14.3 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 56100
|
0.255 USD |
|
1 year ago
Aug 30, 2023
|
Bought 3.02 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 11400
|
0.265 USD |
|
1 year ago
Aug 30, 2023
|
Bought 941 USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 3750
|
0.251 USD |
|
1 year ago
Aug 30, 2023
|
Bought 650 USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 2500
|
0.26 USD |
|
1 year ago
Aug 30, 2023
|
Bought 253 USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 1000
|
0.253 USD |
|
1 year ago
Aug 29, 2023
|
Bought 1.38 K USD
|
Huh Hoyoung
director, 10 percent owner: |
+ 5500
|
0.25 USD |
7. News
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Akari Therapeutics, PLC (NASDAQ:AKTX) , relating to its proposed merger with Peak Bio, Inc. Under the terms of the agreement, Akari shareholders are expected to own approximately 52% of the combined company.
accesswire.com
- 1 month ago
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak's ADC (antibody drug conjugate) platform technology and Akari's PAS-nomacopan Geographic Atrophy (GA) program. Peak's ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari's PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA.
globenewswire.com
- 6 months ago
Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari
MILWAUKEE , March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari. Click here to learn how to join the https://www.ademilaw.com/case/peak-bio-inc or call Guri Ademi toll-free at 866-264-3995.
prnewswire.com
- 8 months ago
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
globenewswire.com
- 8 months ago
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO). The new patent describes properties of potent heteroaryl-substituted Thailanstatin payloads, proprietary non-cleavable and cleavable linkers, and antibody-drug conjugate (ADC) technology derived from it. Peak Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer.
globenewswire.com
- 10 months ago
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing
Pleasanton, CA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer.
globenewswire.com
- 1 year ago
Peak Bio, Inc. Announces Up-listing to OTCQB Market
Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer. The Company today is pleased to announce its successful up-listing from the OTC Pink Market to the OTCQB® Venture Market (the"OTCQB") effective for trading August 31, 2023 at the open. Peak Bio will continue to trade under the ticker symbol "PKBO".
globenewswire.com
- 1 year ago
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases. We are pleased to announce the appointment of one new independent board member, Michael Friedman, MBA as a Class III Director and as a member of the Company's Audit Committee and Compensation Committee.
globenewswire.com
- 1 year ago
Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital
Pleasanton, CA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer. The Company today announced that it has amended its' Common Stock Purchase Agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"). The new amendment leaves in place the Company's existing rights, without the obligation, to sell to White Lion up to $100 million of its common stock over a 36-month period but provides for an additional right to sell shares of common stock to White Lion on an accelerated basis where notice and pricing occur on the same trading day. The Company intends to use the net proceeds from the transaction for working capital to support its clinical and preclinical programs.
globenewswire.com
- 1 year ago
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.
globenewswire.com
- 1 year ago
What Is Going on With Peak Bio (PKBO) Stock Today?
It has been a bumpy week and this Friday isn't any easier following the monthly jobs report. However, that doesn't seem to matter for Peak Bio (NASDAQ: PKBO ), which recently combined in a deal with Ignyte Acquisition.
investorplace.com
- 2 years ago
8. Profile Summary
Peak Bio, Inc. PKBO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 532 K
Dividend Yield
0.00%
Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Contact
3350 W Bayshore Rd., Palo Alto, CA, 94303
https://peak-bio.com
IPO Date
March 15, 2021
Employees
6
Officers
Dr. Satyajit Mitra Ph.D.
Head of Oncology & Executive Director
Ms. Divya Patel CPA
Acting Chief Financial Officer
Dr. Hoyoung Huh M.D., Ph.D.
Executive Chairman